Amgen Inc. | Large-cap | Healthcare
$277.13
-0.71%
| Amgen Stock Comparison:
Amgen vs Eli Lilly andAmgen vs Johnson & JohnsonAmgen vs Merck & CoAmgen vs Gilead SciencesAmgen vs PfizerAmgen vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 33.4B
Gross Profit 20.6B 61.53%
Operating Income 7.3B 21.71%
Net Income 4.1B 12.24%
EPS (Diluted) $7.56

Balance Sheet Metrics

Total Assets 91.8B
Total Liabilities 86.0B
Shareholders Equity 5.9B
Debt to Equity 14.63

Cash Flow Metrics

Operating Cash Flow 11.6B
Free Cash Flow 10.4B

Revenue & Profitability Trend

Amgen Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 33.4B 28.2B 26.3B 26.0B 25.4B
Cost of Goods Sold 12.9B 8.5B 6.4B 6.5B 6.2B
Gross Profit 20.6B 19.7B 19.9B 19.5B 19.3B
Operating Expenses 13.3B 11.8B 10.4B 10.4B 10.1B
Operating Income 7.3B 7.9B 9.6B 9.1B 9.1B
Pre-tax Income 4.6B 7.9B 7.3B 6.7B 8.1B
Income Tax 519.0M 1.1B 794.0M 808.0M 869.0M
Net Income 4.1B 6.7B 6.6B 5.9B 7.3B
EPS (Diluted) $7.56 $12.49 $12.11 $10.28 $12.31

Income Statement Trend

Amgen Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 29.0B 30.3B 22.2B 19.4B 21.1B
Non-Current Assets 62.8B 66.8B 42.9B 41.8B 41.8B
Total Assets 91.8B 97.2B 65.1B 61.2B 62.9B
Liabilities
Current Liabilities 23.1B 18.4B 15.7B 12.2B 11.7B
Non-Current Liabilities 62.9B 72.5B 45.8B 42.3B 41.9B
Total Liabilities 86.0B 90.9B 61.5B 54.5B 53.5B
Equity
Total Shareholders Equity 5.9B 6.2B 3.7B 6.7B 9.4B

Balance Sheet Composition

Amgen Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 4.1B 6.7B 6.6B 5.9B 7.3B
Operating Cash Flow 11.6B 9.8B 7.7B 9.5B 11.9B
Investing Activities
Capital Expenditures -1.1B -1.1B -936.0M -880.0M -608.0M
Investing Cash Flow -1.0B -26.2B -6.0B 733.0M -5.4B
Financing Activities
Dividends Paid -4.8B -4.6B -4.2B -4.0B -3.8B
Financing Cash Flow -9.4B 21.0B -4.0B -8.3B -4.9B
Free Cash Flow 10.4B 7.4B 8.8B 8.4B 9.9B

Cash Flow Trend

Amgen Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 24.84
Forward P/E 13.18
Price to Book 23.60
Price to Sales 4.29
PEG Ratio 13.18

Profitability Ratios

Profit Margin 17.39%
Operating Margin 28.73%
Return on Equity 105.67%
Return on Assets 7.04%

Financial Health

Current Ratio 1.17
Debt to Equity 924.46
Beta 0.50

Per Share Data

EPS (TTM) $10.97
Book Value per Share $11.54
Revenue per Share $63.49

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
amgn 146.5B 24.84 23.60 105.67% 17.39% 924.46
Eli Lilly and 691.8B 62.76 46.33 77.28% 22.67% 243.61
Johnson & Johnson 364.1B 16.83 4.66 29.45% 24.42% 66.90
Merck & Co 198.5B 11.49 4.12 39.29% 27.27% 71.99
Gilead Sciences 132.1B 22.31 6.90 32.65% 20.76% 130.79
Pfizer 136.6B 17.41 1.51 8.62% 12.62% 68.84

Financial data is updated regularly. All figures are in the company's reporting currency.